Lu J - Search Results

1

[The efficacy and safety analysis of bortezomib retreatment in 76 patients with relapsed/refractory multiple myeloma].

Lu J, Hou J, Zhang CY, Yuan ZG, Lan HF, Zhou F, Fan JL, Zhou LL, Du J, Jiang H, Jin LN, Zeng TM, Fu WJ. Lu J, et al. Zhonghua Xue Ye Xue Za Zhi. 2013 Apr;34(4):309-12. doi: 10.3760/cma.j.issn.0253-2727.2013.04.013. Zhonghua Xue Ye Xue Za Zhi. 2013. PMID: 23668202 Chinese.

2

[Clinical consideration of relapsed and refractory multiple myeloma].

Hou J, Lu J. Hou J, et al. Among authors: lu j. Zhonghua Xue Ye Xue Za Zhi. 2013 Apr;34(4):289-90. doi: 10.3760/cma.j.issn.0253-2727.2013.04.005. Zhonghua Xue Ye Xue Za Zhi. 2013. PMID: 23668194 Chinese. No abstract available.

3

[Clinical analysis of newly diagnosed multiple myeloma patients with renal dysfunction].

Zhu W, Lu J, Lu J, Hou J, Huang X, Chen W. Zhu W, et al. Among authors: lu j. Zhonghua Yi Xue Za Zhi. 2015 Mar 17;95(10):741-4. Zhonghua Yi Xue Za Zhi. 2015. PMID: 26080844 Chinese.

4

The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis.

Lu J, Lu J, Liu A, Fu W, Du J, Huang X, Chen W, Hou J. Lu J, et al. Biomed Res Int. 2015;2015:856704. doi: 10.1155/2015/856704. Epub 2015 Nov 8. Biomed Res Int. 2015. PMID: 26640799 Free PMC article.

5

More frequent IgD and reduced CD200 expression in Chinese patients younger than 50 years old with multiple myeloma: a multicenter analysis.

Lu J, Lu J, Chen W, Wang J, Huo Y, Hou J, Huang X. Lu J, et al. Drug Des Devel Ther. 2016 Nov 8;10:3673-3679. doi: 10.2147/DDDT.S100062. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27877018 Free PMC article.

6

hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10.

Xi H, Li L, Du J, An R, Fan R, Lu J, Wu YX, Wu SX, Hou J, Zhao LM. Xi H, et al. Among authors: lu j. Oncol Rep. 2017 Feb;37(2):961-968. doi: 10.3892/or.2016.5318. Epub 2016 Dec 14. Oncol Rep. 2017. PMID: 28000886

7

USP15 inhibits multiple myeloma cell apoptosis through activating a feedback loop with the transcription factor NF-κBp65.

Zhou L, Jiang H, Du J, Li L, Li R, Lu J, Fu W, Hou J. Zhou L, et al. Among authors: lu j. Exp Mol Med. 2018 Nov 20;50(11):1-12. doi: 10.1038/s12276-018-0180-4. Exp Mol Med. 2018. PMID: 30459344 Free PMC article.

8

High Serum Lactate Dehydrogenase adds Prognostic Value to Cardiac Biomarker Staging System for Light Chain Amyloidosis.

He H, Liu J, Jiang H, Du J, Li L, Lu J, Fu W. He H, et al. Among authors: lu j. J Cancer. 2019 Sep 7;10(23):5622-5627. doi: 10.7150/jca.30345. eCollection 2019. J Cancer. 2019. PMID: 31737098 Free PMC article.

9

Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients.

Du J, Lu J, Gao W, Liu J, He H, Li L, Li R, Zhou L, Jiang H, Chen W, Fu W, Hou J. Du J, et al. Among authors: lu j. Ann Hematol. 2020 Aug;99(8):1779-1791. doi: 10.1007/s00277-020-04162-8. Epub 2020 Jun 27. Ann Hematol. 2020. PMID: 32594218

10

Single-cell RNA-seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma.

He H, Li Z, Lu J, Qiang W, Jiang S, Xu Y, Fu W, Zhai X, Zhou L, Qian M, Du J. He H, et al. Among authors: lu j. Clin Transl Med. 2022 Mar;12(3):e757. doi: 10.1002/ctm2.757. Clin Transl Med. 2022. PMID: 35297204 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33,671 results

Search Page

Filters